NCT04632108 2025-09-11
A 1/2 Phase Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ASKB589 in Patients With Locally Advanced or Metastatic Solid Tumors
Jiangsu Aosaikang Pharmaceutical Co., Ltd.
Phase 1/2 Active not recruiting